Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLiron HofstetterYBYotam BronsteinGIGilad Itchaki

Discussion

Loading...

Member takes

Overview

Observational study reports safety and efficacy of venetoclax therapy in CLL patients, suggesting treatment choices impact outcomes.

Key Points

  • To evaluate the real-world efficacy and safety of venetoclax-based therapy in patients with chronic lymphocytic leukemia (CLL).
  • Data from the REVEAL study, a prospective observational study enrolled 304 adult CLL patients in Israel.
  • Patients initiated venetoclax-based regimens across 13 medical centers since February 2019.
  • Endpoints included overall response rate, complete response, progression-free survival, overall survival, and minimal residual disease negativity.
  • 12-month overall response rate was 98% for treatment-naïve patients, with a complete response rate of 75%.
  • Median progression-free survival was not reached for treatment-naïve patients, with 3-year progression-free survival at 83%.
  • In the relapsed/refractory cohort, overall response rate was 95%, with a median progression-free survival of 50.6 months.

Cite This Study

Hofstetter et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85chttps://doi.org/10.1182/blood-2025-3893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia2026
  2. 2Real‐World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single‐Center Comparative Analysis With Randomized Clinical Trials2025 · 1 citations
  3. 3Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience2026
  4. 4Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025
  5. 5Venetoclax-based treatment in adult relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center real-world experience2026